ADHD medications are FDA-approved prescription treatments used to reduce symptoms of attention-deficit\/hyperactivity disorder in both children and adults. The FDA has approved several medications for ADHD in children as young as age 6, and most carry the same approval for adult use.<\/p>\n
All ADHD medications share one core mechanism: they increase the levels of neurotransmitters in the brain \u2014 primarily dopamine and norepinephrine \u2014 that regulate attention, impulse control, and motivation. When those chemical signals aren’t functioning efficiently, the hallmark symptoms of ADHD emerge. Medication helps restore that balance.<\/p>\n
Medication is typically used alongside behavioral therapy, especially in children. For many adults, it’s the cornerstone of a broader treatment plan that may also include coaching, therapy, and lifestyle strategies.<\/p>\n
How Do ADHD Medications Work?<\/strong><\/h2>\nAll ADHD medications increase dopamine and norepinephrine activity in the brain, but they do so through different mechanisms \u2014 and that distinction matters when understanding why some people respond better to one medication than another.<\/p>\n
Stimulants<\/strong> act quickly. Most begin working within 30 to 60 minutes of the first dose. Within the stimulant class, the two main sub-types work slightly differently: amphetamine-based medications (like Adderall and Vyvanse) primarily push neurons to release more dopamine and norepinephrine. Methylphenidate-based medications (like Ritalin and Concerta) primarily block the brain’s reabsorption of those chemicals, allowing them to stay active longer.<\/p>\nNon-stimulants<\/strong> work more gradually. Unlike stimulants, they don’t produce an immediate effect \u2014 most require two to six weeks of consistent use before reaching full effectiveness. They work through separate mechanisms, generally increasing norepinephrine availability or modulating receptors that influence attention and impulse control.<\/p>\nThe result of both approaches is the same: improved ability to focus, reduced impulsivity, and better behavioral regulation.<\/p>\n
Stimulant ADHD Medications<\/strong><\/h2>\nStimulants are the most commonly prescribed treatment for ADHD in both children and adults. They’re classified as Schedule II controlled substances by the DEA, meaning they have recognized medical use but also a meaningful potential for misuse and dependence.<\/p>\n
Research consistently shows that approximately 70\u201380% of people with ADHD<\/a> experience significant symptom improvement with stimulant medication once the right drug and dose are identified.<\/p>\nStimulants come in two formulations: immediate-release (IR), which lasts 3\u20136 hours and may require multiple daily doses, and extended-release (ER or XR), which provides coverage for 8\u201314 hours and is typically taken once daily.<\/p>\n
Amphetamine-Based Stimulants<\/strong><\/h3>\nAmphetamine medications are among the most widely prescribed ADHD treatments in the United States. They work by prompting neurons to release larger amounts of dopamine and norepinephrine into the synaptic gap. <\/p>\n
Adderall (amphetamine\/dextroamphetamine) is available in both immediate-release and extended-release (Adderall XR) forms. It’s one of the most commonly prescribed ADHD medications and has decades of clinical use behind it. For an in-depth look at how Adderall compares to other stimulants, see our guide to Adderall vs. Ritalin<\/a>.<\/p>\nVyvanse (lisdexamfetamine) is an extended-release amphetamine with an important design difference: it’s a prodrug, meaning it’s inactive until your body metabolizes it. After ingestion, enzymes in the bloodstream convert it to active dextroamphetamine. This gradual conversion produces a smoother, more consistent effect and makes it harder to misuse by crushing or snorting \u2014 a meaningful consideration for people with a history of substance use. We cover Adderall vs. Vyvanse<\/a> in detail separately.<\/p>\nDexedrine (dextroamphetamine) is an older amphetamine option, prescribed less frequently today but FDA-approved and effective for some patients who don’t respond well to mixed-salt formulations.<\/p>\n
Methylphenidate-Based Stimulants<\/strong><\/h3>\nMethylphenidate medications work primarily by blocking the brain’s reuptake of dopamine and norepinephrine \u2014 keeping those chemicals active in the synapse for longer rather than pushing for greater release.<\/p>\n
Ritalin (methylphenidate) is an immediate-release tablet typically taken two to three times daily. It has one of the longest clinical track records in ADHD treatment and is often tried first in younger children because of its established safety profile and the ability to titrate doses precisely.<\/p>\n
Concerta (methylphenidate ER) delivers extended-release methylphenidate over 10\u201312 hours using a unique osmotic pump system. One daily dose is designed to provide consistent, steady-state coverage \u2014 useful for people whose schedules make multiple dosing impractical.<\/p>\n
Focalin (dexmethylphenidate) is a refined form of methylphenidate \u2014 it uses only the more active portion of the compound. Available in both IR and XR formulations, it’s prescribed when a lower effective dose is preferred.<\/p>\n
Non-Stimulant ADHD Medications<\/strong><\/h2>\nNon-stimulants are not controlled substances. They carry no meaningful risk of addiction and don’t produce the same immediate effect as stimulants \u2014 but for a significant number of people, they’re the right clinical choice.<\/p>\n
ADHD specialists typically recommend non-stimulants when: stimulants haven’t worked or caused intolerable side effects, the patient has a co-occurring anxiety disorder that stimulants worsen, or there’s a personal or family history of substance use that makes stimulant therapy higher risk.<\/p>\n
Atomoxetine (generic; formerly Strattera)<\/strong><\/h3>\nAtomoxetine was the first non-stimulant medication approved by the FDA for ADHD. It’s a selective norepinephrine reuptake inhibitor (SNRI) \u2014 it increases norepinephrine availability specifically, without the dopamine surge that stimulants produce.<\/p>\n
It’s taken once or twice daily and approved for children age 6 and older and adults. Full effectiveness typically requires four to six weeks of consistent use. <\/p>\n
Important safety note:<\/strong> Atomoxetine carries aboxed warning from the FDA<\/a> for increased risk of suicidal ideation in short-term studies in children and adolescents with ADHD. Patients started on atomoxetine should be monitored closely for suicidal thinking, clinical worsening, and unusual changes in behavior \u2014 particularly early in treatment. Families and caregivers should maintain close communication with the prescriber. The brand name Strattera was discontinued in 2023; generic atomoxetine is widely available.<\/p>\nViloxazine (Qelbree)<\/strong><\/h3>\nViloxazine is a newer non-stimulant, FDA-approved for ADHD in children ages 6 and older and adults \u2014 making it the first novel non-stimulant option approved for adults in two decades (approved for adults in 2022). Like atomoxetine, it’s taken once daily. It works through a similar norepinephrine-focused mechanism but with a somewhat different receptor profile, which may account for differences in tolerability between the two.<\/p>\n
It’s not a controlled substance and carries no addiction risk. For patients who didn’t tolerate atomoxetine well, viloxazine is a distinct option worth discussing with a prescriber.<\/p>\n
Guanfacine (Intuniv) and Clonidine (Kapvay)<\/strong><\/h3>\nBoth guanfacine and clonidine are alpha-2 adrenergic agonists \u2014 medications originally developed to treat high blood pressure that were later found to reduce hyperactivity, impulsivity, and distractibility in people with ADHD.<\/p>\n
The extended-release versions \u2014 Intuniv (guanfacine) and Kapvay (clonidine) \u2014 are FDA-approved for ADHD in children and are sometimes used as adjunctive therapy alongside stimulants in adults.<\/p>\n
Key consideration: both can cause drowsiness, especially when starting treatment, and can lower blood pressure. They’re not typically a first-line standalone choice for adults, but they play a meaningful role in multi-medication ADHD treatment plans.<\/p>\n
ADHD Medication Comparison Table<\/strong><\/h2>\nThe table below compares the most commonly prescribed ADHD medications by class, formulation, typical duration, and key clinical notes.<\/p>\n\n
Non-stimulants<\/strong> work more gradually. Unlike stimulants, they don’t produce an immediate effect \u2014 most require two to six weeks of consistent use before reaching full effectiveness. They work through separate mechanisms, generally increasing norepinephrine availability or modulating receptors that influence attention and impulse control.<\/p>\n The result of both approaches is the same: improved ability to focus, reduced impulsivity, and better behavioral regulation.<\/p>\n Stimulants are the most commonly prescribed treatment for ADHD in both children and adults. They’re classified as Schedule II controlled substances by the DEA, meaning they have recognized medical use but also a meaningful potential for misuse and dependence.<\/p>\n Research consistently shows that approximately 70\u201380% of people with ADHD<\/a> experience significant symptom improvement with stimulant medication once the right drug and dose are identified.<\/p>\n Stimulants come in two formulations: immediate-release (IR), which lasts 3\u20136 hours and may require multiple daily doses, and extended-release (ER or XR), which provides coverage for 8\u201314 hours and is typically taken once daily.<\/p>\n Amphetamine medications are among the most widely prescribed ADHD treatments in the United States. They work by prompting neurons to release larger amounts of dopamine and norepinephrine into the synaptic gap. <\/p>\n Adderall (amphetamine\/dextroamphetamine) is available in both immediate-release and extended-release (Adderall XR) forms. It’s one of the most commonly prescribed ADHD medications and has decades of clinical use behind it. For an in-depth look at how Adderall compares to other stimulants, see our guide to Adderall vs. Ritalin<\/a>.<\/p>\n Vyvanse (lisdexamfetamine) is an extended-release amphetamine with an important design difference: it’s a prodrug, meaning it’s inactive until your body metabolizes it. After ingestion, enzymes in the bloodstream convert it to active dextroamphetamine. This gradual conversion produces a smoother, more consistent effect and makes it harder to misuse by crushing or snorting \u2014 a meaningful consideration for people with a history of substance use. We cover Adderall vs. Vyvanse<\/a> in detail separately.<\/p>\n Dexedrine (dextroamphetamine) is an older amphetamine option, prescribed less frequently today but FDA-approved and effective for some patients who don’t respond well to mixed-salt formulations.<\/p>\n Methylphenidate medications work primarily by blocking the brain’s reuptake of dopamine and norepinephrine \u2014 keeping those chemicals active in the synapse for longer rather than pushing for greater release.<\/p>\n Ritalin (methylphenidate) is an immediate-release tablet typically taken two to three times daily. It has one of the longest clinical track records in ADHD treatment and is often tried first in younger children because of its established safety profile and the ability to titrate doses precisely.<\/p>\n Concerta (methylphenidate ER) delivers extended-release methylphenidate over 10\u201312 hours using a unique osmotic pump system. One daily dose is designed to provide consistent, steady-state coverage \u2014 useful for people whose schedules make multiple dosing impractical.<\/p>\n Focalin (dexmethylphenidate) is a refined form of methylphenidate \u2014 it uses only the more active portion of the compound. Available in both IR and XR formulations, it’s prescribed when a lower effective dose is preferred.<\/p>\n Non-stimulants are not controlled substances. They carry no meaningful risk of addiction and don’t produce the same immediate effect as stimulants \u2014 but for a significant number of people, they’re the right clinical choice.<\/p>\n ADHD specialists typically recommend non-stimulants when: stimulants haven’t worked or caused intolerable side effects, the patient has a co-occurring anxiety disorder that stimulants worsen, or there’s a personal or family history of substance use that makes stimulant therapy higher risk.<\/p>\n Atomoxetine was the first non-stimulant medication approved by the FDA for ADHD. It’s a selective norepinephrine reuptake inhibitor (SNRI) \u2014 it increases norepinephrine availability specifically, without the dopamine surge that stimulants produce.<\/p>\n It’s taken once or twice daily and approved for children age 6 and older and adults. Full effectiveness typically requires four to six weeks of consistent use. <\/p>\n Important safety note:<\/strong> Atomoxetine carries aboxed warning from the FDA<\/a> for increased risk of suicidal ideation in short-term studies in children and adolescents with ADHD. Patients started on atomoxetine should be monitored closely for suicidal thinking, clinical worsening, and unusual changes in behavior \u2014 particularly early in treatment. Families and caregivers should maintain close communication with the prescriber. The brand name Strattera was discontinued in 2023; generic atomoxetine is widely available.<\/p>\n Viloxazine is a newer non-stimulant, FDA-approved for ADHD in children ages 6 and older and adults \u2014 making it the first novel non-stimulant option approved for adults in two decades (approved for adults in 2022). Like atomoxetine, it’s taken once daily. It works through a similar norepinephrine-focused mechanism but with a somewhat different receptor profile, which may account for differences in tolerability between the two.<\/p>\n It’s not a controlled substance and carries no addiction risk. For patients who didn’t tolerate atomoxetine well, viloxazine is a distinct option worth discussing with a prescriber.<\/p>\n Both guanfacine and clonidine are alpha-2 adrenergic agonists \u2014 medications originally developed to treat high blood pressure that were later found to reduce hyperactivity, impulsivity, and distractibility in people with ADHD.<\/p>\n The extended-release versions \u2014 Intuniv (guanfacine) and Kapvay (clonidine) \u2014 are FDA-approved for ADHD in children and are sometimes used as adjunctive therapy alongside stimulants in adults.<\/p>\n Key consideration: both can cause drowsiness, especially when starting treatment, and can lower blood pressure. They’re not typically a first-line standalone choice for adults, but they play a meaningful role in multi-medication ADHD treatment plans.<\/p>\n The table below compares the most commonly prescribed ADHD medications by class, formulation, typical duration, and key clinical notes.<\/p>\nStimulant ADHD Medications<\/strong><\/h2>\n
Amphetamine-Based Stimulants<\/strong><\/h3>\n
Methylphenidate-Based Stimulants<\/strong><\/h3>\n
Non-Stimulant ADHD Medications<\/strong><\/h2>\n
Atomoxetine (generic; formerly Strattera)<\/strong><\/h3>\n
Viloxazine (Qelbree)<\/strong><\/h3>\n
Guanfacine (Intuniv) and Clonidine (Kapvay)<\/strong><\/h3>\n
ADHD Medication Comparison Table<\/strong><\/h2>\n
![\"Dr.](\"https:\/\/discover-recovery-1410e39.ingress-florina.ewp.live\/wp-content\/uploads\/2025\/03\/Kevin_Fischer1.jpg\")
<\/p>\n